ERNA — Eterna Therapeutics Share Price
0.000.00%
Last trade - 00:00- $12.12m
- $12.52m
- $0.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.43 | ||
| Price to Tang. Book | 64.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 178.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.66% | ||
| Return on Equity | -302.47% | ||
| Operating Margin | -31080.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 19.81 | 5.8 | n/a | n/a | 0.07 | n/a | n/a | -68.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
Directors
- Allen Wolff CHM (49)
- Lynn Mason EVP (42)
- Jay Sial CAD (57)
- Kevin D' Amour CSO (48)
- Sandra Gurrola VFN (54)
- Ronald Guido OTH (62)
- Roger Sidhu OTH (45)
- Charles Cherington IND (57)
- Erin Enright IND (60)
- Dennis Langer IND (69)
- Erich Mohr IND (66)
- Heather Redman IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 13th, 1984
- Public Since
- August 29th, 1991
- No. of Shareholders
- 155
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,410,331
- Address
- 1035 Cambridge Street, Suite 18A, CAMBRIDGE, 02141
- Web
- https://eternatx.com/
- Phone
- +1 2125821199
- Auditors
- Marcum LLP
Upcoming Events for ERNA
Eterna Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Eterna Therapeutics Inc Earnings Release
Similar to ERNA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Eterna Therapeutics share price?
As of Today at 19:08 UTC, shares in Eterna Therapeutics are trading at $2.24. This share price information is delayed by 15 minutes.
How has the Eterna Therapeutics share price performed this year?
Shares in Eterna Therapeutics last closed at $2.24 and the price had moved by -31.5% over the past 365 days. In terms of relative price strength the Eterna Therapeutics share price has underperformed the S&P500 Index by -44.68% over the past year.
What are the analyst and broker recommendations for Eterna Therapeutics?
The overall consensus recommendation for Eterna Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Eterna Therapeutics dividend yield?
Eterna Therapeutics does not currently pay a dividend.
Does Eterna Therapeutics pay a dividend?
Eterna Therapeutics does not currently pay a dividend.
When does Eterna Therapeutics next pay dividends?
Eterna Therapeutics does not currently pay a dividend.
How do I buy Eterna Therapeutics shares?
To buy shares in Eterna Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eterna Therapeutics?
As of the previous close price of $2.24, shares in Eterna Therapeutics had a market capitalisation of $12.12m.
Where are Eterna Therapeutics shares listed?
Here are the trading details for Eterna Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ERNA
What kind of share is Eterna Therapeutics?
Based on an overall assessment of its quality, value and momentum Eterna Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eterna Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Eterna Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eterna Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -11.14%.
As of the last closing price of $2.24, shares in Eterna Therapeutics were trading +14.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eterna Therapeutics PE Ratio?
The Eterna Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eterna Therapeutics?
Eterna Therapeutics' management team is headed by:
- Allen Wolff - CHM
- Lynn Mason - EVP
- Jay Sial - CAD
- Kevin D' Amour - CSO
- Sandra Gurrola - VFN
- Ronald Guido - OTH
- Roger Sidhu - OTH
- Charles Cherington - IND
- Erin Enright - IND
- Dennis Langer - IND
- Erich Mohr - IND
- Heather Redman - IND